

ORIGINAL ARTICLE

# A Longitudinal, Population-Based, Cohort Study of Childhood Asthma Followed to Adulthood

Malcolm R. Sears, M.B., Justina M. Greene, Andrew R. Willan, Ph.D., Elizabeth M. Wiecek, M.D., D. Robin Taylor, M.D., Erin M. Flannery, Jan O. Cowan, G. Peter Herbison, M.Sc., Phil A. Silva, Ph.D., and Richie Poulton, Ph.D.

## ABSTRACT

### BACKGROUND

The outcome of childhood asthma in adults has been described in high-risk cohorts, but few population-based studies have reported the risk factors for persistence and relapse.

### METHODS

We assessed children born from April 1972 through March 1973 in Dunedin, New Zealand, repeatedly from 9 to 26 years of age with questionnaires, pulmonary-function tests, bronchial-challenge testing, and allergy testing.

### RESULTS

By the age of 26 years, 51.4 percent of 613 study members with complete respiratory data had reported wheezing at more than one assessment. Eighty-nine study members (14.5 percent) had wheezing that persisted from childhood to 26 years of age, whereas 168 (27.4 percent) had remission, but 76 (12.4 percent) subsequently relapsed by the age of 26. Sensitization to house dust mites predicted the persistence of wheezing (odds ratio, 2.41;  $P=0.001$ ) and relapse (odds ratio, 2.18;  $P=0.01$ ), as did airway hyperresponsiveness (odds ratio for persistence, 3.00;  $P<0.001$ ; odds ratio for relapse, 3.03;  $P<0.001$ ). Female sex predicted the persistence of wheezing (odds ratio, 1.71;  $P=0.03$ ), as did smoking at the age of 21 years (odds ratio, 1.84;  $P=0.01$ ). The earlier the age at onset, the greater the risk of relapse (odds ratio, 0.89 per year of increase in the age at onset;  $P<0.001$ ). Pulmonary function was consistently lower in those with persistent wheezing than in those without persistent wheezing.

### CONCLUSIONS

In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission. The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset. These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.

From the Departments of Medicine (M.R.S., J.M.G.), and Clinical Epidemiology and Biostatistics (A.R.W., E.M.W.), McMaster University, Hamilton, Ont., Canada; and the Department of Medicine (D.R.T., E.M.F., J.O.C.), the Department of Preventive and Social Medicine (G.P.H.), and the Dunedin Multidisciplinary Health and Development Research Unit (P.A.S., R.P.), University of Otago, Dunedin, New Zealand. Address reprint requests to Dr. Sears at the Firestone Institute for Respiratory Health, McMaster University and St. Joseph's Healthcare, 50 Charlton Ave. E., Hamilton, ON L8N 4A6, Canada, or at [searsm@mcmaster.ca](mailto:searsm@mcmaster.ca).

N Engl J Med 2003;349:1414-22.  
Copyright © 2003 Massachusetts Medical Society.

**T**HE INCREASE IN THE PREVALENCE OF wheezing disorders, whether or not they are labeled as asthma, could be related to an increased incidence or an increased persistence of asthma.<sup>1,2</sup> Studies of the natural history of asthma have often focused on selected populations. However, the outcomes in children referred to university clinics<sup>3,4</sup> or selected in high-risk cohorts<sup>5</sup> may not reflect the outcomes in the general population, since the initial selection criteria may predetermine the risk factors for persistence or relapse.<sup>6</sup>

Most children attending asthma specialty clinics who have been followed have had atopy, with frequent symptoms and airway hyperresponsiveness, indicating severe disease that is likely to persist. The effects of sex, age at onset, and smoking on the outcome have been uncertain in such children<sup>7,8</sup> and in high-risk cohorts selected according to the presence of parental atopy.<sup>5,9</sup> The few population-based epidemiologic studies of outcomes of childhood asthma differ in the frequency of assessment, cohort-retention rates, and the use of quantitative measurements.<sup>10-13</sup> In particular, repeated lung-function measurements have been reported infrequently.<sup>14-16</sup> We report outcomes in an unselected, population-based birth cohort of over 1000 New Zealand children followed to adulthood.

---

## METHODS

---

### STUDY MEMBERS

The Dunedin Multidisciplinary Health and Development Study is a longitudinal investigation of health and behavior in a complete birth cohort.<sup>17-21</sup> The study members were born in Dunedin, New Zealand, between April 1972 and March 1973. Of 1139 children born during that period and residing in the province of Otago, New Zealand, at the age of three years, 1037 (91 percent, 52 percent of whom were boys) participated in the first follow-up assessment at three years of age. The cohort families represented the full range of socioeconomic status in New Zealand's South Island and were primarily of European extraction.

The children were seen every 2 years between 3 and 15 years of age and then were seen at 18, 21, and 26 years. Respiratory questionnaires were completed and lung-function measurements were performed at the ages of 9, 11, 13, 15, 18, 21, and 26 years; airway hyperresponsiveness to methacholine was determined at the ages of 9, 11, 13, 15, and 21

years; atopy was determined at 11 years (IgE levels only), 13 years (skin tests only), and 21 years (IgE levels and skin tests); and responsiveness to a bronchodilator was determined at 18 and 26 years.

The research ethics committee of the Otago Hospital Board approved each assessment. The participants gave written informed consent from the age of 18 years; before that age, a parent or guardian gave written informed consent, and the child gave oral assent.

### FOLLOW-UP

For accurate classification of remission, relapse, or persistence of asthma, study members who completely missed any assessment were excluded from the analysis. For an assessment to be included, at least a respiratory questionnaire had to be completed. The characteristics of the study members who were included were compared with the characteristics of those not included. The outcome characteristics of those included and all study members participating at the age of 26 years were also compared.

### QUESTIONNAIRES

When the child was nine years old, the accompanying adult (usually the mother) answered detailed questions about the child's symptoms and illnesses, providing a retrospective history of respiratory events between birth and the age of nine, including frequency, severity, trigger factors, and treatment (specifically, the use of bronchodilator and corticosteroid medications).<sup>19</sup> Subsequently, similar questions were answered by the study member. From the age of 18 years, the study member completed the self-administered questionnaire used in the European Community Respiratory Health Study<sup>22</sup> and questions from the American Thoracic Society questionnaire<sup>23</sup> before answering the interviewer-administered questionnaire.

### SKIN TESTS

Skin-prick testing was performed at the ages of 13 years (714 participants) and 21 years (885 participants) to determine sensitivity to house dust mites (*Dermatophagoides pteronyssinus*) (Bencard), grass, cat dander, dog dander, horse dander, kapok, wool, *Aspergillus fumigatus*, alternaria, penicillium, and cladosporium (Hollister-Stier).<sup>20</sup> The positive and negative controls were 0.1 percent histamine and diluent, respectively. The response was measured as the mean diameter of the resulting wheal.

**LUNG-FUNCTION TESTS**

Three measurements of forced vital capacity (FVC) and forced expiratory volume in one second (FEV<sub>1</sub>), obtained in the absence of recent use (within six hours) of a bronchodilator, were recorded on a Godart water-sealed spirometer at the ages of 9, 11, 13, 15 and 21 years (when methacholine challenges were also performed), a Morgan rolling-seal spirometer at the age of 18 years, and a SensorMedics body plethysmograph at the age of 26 years. The instruments were calibrated daily with a 3-liter syringe. The measurements were made between 1 p.m. and 4 p.m. The predicted values at 26 years of age were based on a study of New Zealand adults.<sup>24</sup>

**AIRWAY RESPONSIVENESS**

Methacholine challenge was performed in all consenting study members at the ages of 9, 11, 13, 15, and 21 years with the use of an abbreviated validated protocol<sup>21</sup> modified from that of Chai et al.<sup>25</sup> Challenge was not performed in those with airflow obstruction (FEV<sub>1</sub> of less than 75 percent of the FVC at 9 and 11 years of age and of less than 70 percent of the FVC at older ages), but spirometry was repeated 10 minutes after they had inhaled nebulized albuterol (5 mg per milliliter) for 2 minutes. At 18 and 26 years of age, bronchodilator responsiveness was determined in all consenting study members.

**DEFINITIONS**


Figure 1 illustrates the definitions of different patterns of wheezing. All wheezing, irrespective of causal factors, was included except for wheezing occurring only once or twice annually and lasting less than one hour. Wheezing reported at every as-

essment after its first mention was classified as persistent wheezing. Remission was defined as the absence of wheezing after wheezing had been reported at two or more successive prior assessments. Relapse was recorded if wheezing was reported at two or more successive assessments, then was absent at one or more successive assessments, and then was reported at all subsequent assessments. Intermittent wheezing was characterized by the presence of symptoms at some assessments but not others and not at two consecutive assessments and not fitting the patterns described above. Wheezing reported at one assessment only was classified as transient wheezing.

Airway hyperresponsiveness was defined by a value for methacholine PC<sub>20</sub> (the concentration of methacholine causing a 20 percent decrease in the FEV<sub>1</sub>) of 8 mg per milliliter or less or an increase in the FEV<sub>1</sub> of at least 10 percent from base line in response to a bronchodilator. Atopy was defined by a wheal diameter at least 2 mm greater than that of the wheal produced by the diluent control.

**STATISTICAL ANALYSIS**

The data were analyzed with SAS software. The characteristics of the study members and the prevalences of persistence, remission, and relapse were described with summary statistics. Logistic regression was used to estimate unadjusted and adjusted odds ratios, significance levels, and confidence intervals for factors associated with persistence or relapse. Trends and differences between outcome groups in mean measures of pulmonary function were assessed with generalized estimating equations incorporating the repeated nature of these data.



## RESULTS

**STUDY SAMPLE**

At the age of 9 years, 815 study members (78.6 percent of the cohort of 1037) completed respiratory questionnaires, as did 802 (77.3 percent) at 11 years, 735 (70.9 percent) at 13 years, 972 (93.7 percent) at 15 years, 868 (83.7 percent) at 18 years, 957 (92.3 percent) at 21 years, and 954 (92.0 percent) at 26 years. Because of the reduced numbers at 11 and 13 years, only 613 study members (59.1 percent of the total, of whom 317 were male) provided respiratory data at every assessment. These 613 make up the sample for the analysis of persistence, remission, and relapse of wheezing, since those with missing data cannot be accurately classified.

**REPRESENTATIVENESS OF THE SAMPLE**

There were no significant differences in sex ratio, family history of asthma and hay fever, symptoms, proportion with atopy, lung-function measurements, or prevalence of airway hyperresponsiveness between the 613 study members with complete respiratory data and the original cohort of 1037, or between the 613 study members and all study members undergoing these investigations at particular ages. As compared with those not attending every assessment, the 613 were more likely to report current asthma or wheezing at 9 years and were more likely to be sensitive to house dust mites or to any allergen at 13 and 21 years. However, they were not more likely to have airway hyperresponsiveness at 9 years and were less likely to have airway hyperresponsiveness at 21 years (Table 1). At 26 years, there were no significant differences in the prevalences of asthma, wheezing, asthma treatment, or smoking or in lung-function measurements between those seen at every assessment and those not seen at every assessment (Table 1). Hence, the 613 with complete outcome data are generally representative of the base cohort.

**PERSISTENCE OF WHEEZING**

Of the study members, 72.6 percent had reported wheezing during at least one assessment by the age of 26 years, and 51.4 percent had reported such wheezing at more than one assessment. At this age, 26.9 percent of the study members were currently wheezing. In 14.5 percent, wheezing had persisted from onset, whereas 12.4 percent had had a remission followed by a relapse by the age of 26 years (Table 2). Another 15.0 percent remained in remis-

sion, 9.5 percent had intermittent symptoms, and 21.2 percent had reported symptoms at only one assessment.

**TRANSIENT WHEEZING**

Wheezing at only one assessment (transient wheezing) was reported by 130 of the 613 study members (21.2 percent) (Table 2), including 28 (4.6 percent) who reported wheezing only at the age of 26 years. As compared with the group of study members who never reported wheezing, the group with transient wheezing had a significantly higher prevalence of atopy for house dust mites at the age of 13 years (23.3 percent vs. 12.7 percent,  $P=0.02$ ), and nonsignificant trends toward an increased prevalence of atopy at 21 years of age and toward smoking.

**RELATION OF PERSISTENCE AND REMISSION TO RISK FACTORS**

Table 3 shows the relations between outcomes at the age of 26 years and atopy, airway hyperresponsiveness, parental and personal smoking, birth order, and whether the study member had been breastfed. At the age of 26 years, study members with persistent or relapsing wheezing had higher prevalences of sensitivity to house dust mites ( $P<0.001$ ) and cat allergen ( $P<0.001$ ) and of airway hyperresponsiveness ( $P<0.001$ ) and lower lung-function measurements ( $P<0.001$ ) than those whose wheezing did not persist or relapse.

Table 4 shows the odds ratios for persistence and relapse of wheezing according to univariate and multivariate models. The highest odds ratios associated with either persistence or relapse were for airway hyperresponsiveness (determined as either a value for methacholine  $PC_{20}$  that was less than 8 mg per milliliter or an increase in the value for  $FEV_1$  of more than 10 percent from base line in response to a bronchodilator) between the ages of 9 and 21 years and for a positive skin test for house dust mites at the age of 13 years. Female sex and smoking also predicted persistence, whereas an early age at onset predicted relapse. Other factors that were significant in the univariate analysis were not independently significant in multivariate analyses.

Throughout childhood and into adulthood, study members with persistent wheezing had consistently lower lung-function measurements, expressed as the ratio of  $FEV_1$  to FVC, than study members who never reported wheezing (Fig. 2). The slopes of change in the  $FEV_1$ :FVC ratio over time from the ages of 9 to 26 years in any outcome category for ei-

**Table 1. Characteristics of the 613 Study Members Who Provided Respiratory Data at All Assessments from 9 to 26 Years of Age, as Compared with the Characteristics of Those Not Providing Data at All Assessments.\***

Characteristic†	Prevalence in 613 Study Members Seen at All Assessments	Prevalence in Study Members Not Seen at All Assessments	Study Members Included in Comparison
	% (no. of study members with data)		
Male sex	51.7 (613)	51.4 (424)	Full cohort
Maternal asthma	9.0 (589)	5.9 (271)	Seen at 7 yr
Paternal asthma	9.1 (583)	9.0 (266)	Seen at 7 yr
Maternal hay fever	21.8 (588)	16.9 (272)	Seen at 7 yr
Paternal hay fever	12.6 (581)	11.7 (265)	Seen at 7 yr
Asthma at 9 yr	9.0 (613)	3.5 (202)‡	Seen at 9 yr
Wheezing at 9 yr	21.7 (613)	14.4 (202)‡	Seen at 9 yr
Atopy at 13 yr (any skin-test wheal ≥2 mm)	46.9 (597)	33.3 (117)§	Skin-tested at 13 yr
Positive for house-dust-mite allergen at 13 yr	31.3 (597)	22.2 (117)‡	Skin-tested at 13 yr
Positive for house-dust-mite allergen at 21 yr	58.6 (577)	49.7 (308)‡	Skin-tested at 21 yr
PC <sub>20</sub> ≤8 mg/ml at 9 yr	15.6 (578)	11.0 (191)	Methacholine-challenged at 9 yr
PC <sub>20</sub> ≤8 mg/ml at 21 yr	6.5 (543)	10.3 (301)‡	Methacholine-challenged at 21 yr
Asthma at 26 yr	20.7 (613)	16.4 (367)	Seen at 26 yr
Wheezing at 26 yr	36.1 (613)	37.6 (359)	Seen at 26 yr
Asthma treatment at 26 yr	17.8 (612)	13.2 (348)	Seen at 26 yr
Smoking at 26 yr	33.8 (612)	40.5 (348)	Seen at 26 yr
FEV <sub>1</sub> at 26 yr (% of predicted)	101.5 (597)	101.1 (335)	Spirometry at 26 yr
FEV <sub>1</sub> :FVC at 26 yr (%)	82.0 (597)	82.7 (335)	Spirometry at 26 yr

\* Study members are described as “seen” if they attended the assessment and provided respiratory data.

† PC<sub>20</sub> denotes the concentration of methacholine causing a 20 percent decrease in forced expiratory volume in one second (FEV<sub>1</sub>), and FVC denotes forced vital capacity.

‡ P<0.05.

§ P<0.01.

**Table 2. Outcomes at Age 26 Years among 613 Study Members Who Provided Respiratory Data at Every Assessment, According to Sex.**

Outcome	Male Study Members (N=317)	Female Study Members (N=296)	Total (N=613)
	% (no. of study members)		
Persistent wheezing (from onset to 26 yr)	12.6 (40)	16.6 (49)	14.5 (89)
Relapse (wheezing stopped then recurred)	12.9 (41)	11.8 (35)	12.4 (76)
In remission (free of wheezing at 26 yr)	15.5 (49)	14.5 (43)	15.0 (92)
Intermittent wheezing	9.5 (30)	9.5 (28)	9.5 (58)
Transient wheezing (reported at only one assessment)	19.9 (63)	22.6 (67)	21.2 (130)
Wheezing never reported	29.7 (94)	25.0 (74)	27.4 (168)

**Table 3. Characteristics of Study Members with Different Patterns of Wheezing.\***

Characteristic	Wheezing Pattern					Never Wheezed	P for Trend†
	Persistent from Onset	Relapse	Remission	Intermittent	Transient		
	<i>percent (number of study members with data)</i>						
Male sex	44.9 (89)	53.9 (76)	53.3 (92)	51.7 (58)	48.5 (130)	56.0 (168)	—
Smoking at 18 yr	40.5 (89)	35.5 (76)	31.5 (92)	37.9 (58)	30.8 (130)	14.9 (168)	—
Smoking at 26 yr	46.1 (89)	43.4 (76)	35.9 (92)	43.1 (58)	32.3 (130)	19.6 (168)	—
Father smoked when study member was a child	39.8 (88)	56.6 (76)	54.4 (92)	62.1 (58)	50.0 (130)	44.1 (168)	—
Mother smoked when study member was a child	37.1 (89)	40.8 (76)	46.7 (92)	50.0 (58)	36.9 (130)	38.7 (168)	—
Positive skin test for house-dust-mite allergen at 13 yr	55.7 (88)	54.9 (71)	35.6 (87)	30.4 (56)	23.3 (129)	12.7 (166)	<0.001
Positive skin test for cat allergen at 13 yr	28.4 (88)	26.8 (71)	21.8 (87)	14.3 (56)	7.8 (129)	4.2 (166)	<0.001
Positive skin test for house-dust-mite allergen at 21 yr	77.5 (80)	73.9 (69)	64.8 (88)	55.6 (54)	54.8 (124)	43.2 (162)	<0.001
Positive skin test for cat allergen at 21 yr	53.8 (80)	47.8 (69)	35.2 (88)	24.1 (54)	18.6 (124)	11.7 (162)	<0.001
PC <sub>20</sub> ≤ 8 mg/ml or BDR ≥ 10% at 9 yr	42.5 (87)	43.1 (72)	23.9 (92)	15.5 (58)	5.6 (126)	3.6 (165)	<0.001
PC <sub>20</sub> ≤ 8 mg/ml or BDR ≥ 10% at any assessment from 9–21 yr	52.8 (89)	56.6 (76)	31.5 (92)	27.6 (58)	8.6 (128)	7.2 (167)	<0.001
FEV <sub>1</sub> at 26 yr (% of predicted)	96.6 (85)	95.7 (76)	100.6 (89)	103.7 (58)	102.5 (126)	105.6 (161)	<0.001
FEV <sub>1</sub> :FVC at 26 yr (%)‡	78.0 (86)	79.1 (76)	83.1 (89)	82.2 (58)	83.4 (126)	83.7 (162)	<0.001
Firstborn	41.6 (89)	32.9 (76)	32.6 (92)	34.5 (58)	36.2 (130)	43.5 (168)	—
Breast-fed ≥ 4 wk	57.3 (89)	52.6 (76)	59.8 (92)	37.9 (58)	49.2 (130)	51.2 (168)	—

\* PC<sub>20</sub> denotes the concentration of methacholine causing a 20 percent decrease in the forced expiratory volume in one second (FEV<sub>1</sub>), BDR the response of FEV<sub>1</sub> to a bronchodilator (increase from base line), and FVC the forced vital capacity.

† The trend is across categories of frequency from persistent from onset to never wheezed.

‡ FEV<sub>1</sub> (% of predicted) was based on a prediction formula from a New Zealand population<sup>24</sup> and was measured without the use of a bronchodilator.

ther sex were not significantly different from those for study members who never reported wheezing. When generalized estimating equations incorporating the repeated nature of the data in the analysis were used, the mean FEV<sub>1</sub>:FVC ratio for male study members with persistent wheezing was 6.8 percent less than the mean for male study members who never reported wheezing ( $P < 0.001$ ); for male study members who had a relapse, the difference was -6.5 percent ( $P < 0.001$ ). The differences in the mean FEV<sub>1</sub>:FVC ratio between those with remission, intermittent wheezing, or transient wheezing and those who never reported wheezing were nonsignificant (-0.8 percent, -1.9 percent, and -1.1 percent, respectively). Among female study members, the differences in the FEV<sub>1</sub>:FVC ratio, as compared with those who never reported wheezing, were -4.7 percent for persistent wheezing ( $P < 0.001$ ), -2.7 percent for relapse ( $P = 0.003$ ), -2.3 percent for remission ( $P = 0.022$ ), -1.8 percent for intermittent wheezing, and -0.1 percent for transient wheezing.

The lung-function measurements in study mem-

bers with persistent wheezing who reported having used inhaled corticosteroids at any time were substantially lower at all ages and for both sexes than they were in those with persistent wheezing who had never used inhaled corticosteroids; the mean difference in the FEV<sub>1</sub>:FVC ratio was -7.2 percent in male study members and -8.2 percent in female study members. Similarly, in the group with persistent wheezing, lung-function measurements were lower in study members who had airway hyperresponsiveness on three or more occasions than in those who had hyperresponsiveness less often (mean difference, -7.4 percent for male and female study members combined).

## DISCUSSION

Our study of an unselected, population-based birth cohort with the use of seven respiratory assessments from childhood into adulthood provides insights into the risk factors for the persistence and relapse of childhood asthma and for pulmonary-function

**Table 4. Odds Ratios for Factors Predicting Persistence of Wheezing from Onset to the Age of 26 Years or Relapse, by the Age of 26 Years.\***

Model	Persistence		Relapse	
	OR (95% CI)	P Value	OR (95% CI)	P Value
Univariate				
PC <sub>20</sub> or BDR at 9 yr	4.32 (2.64–7.06)	<0.001	6.82 (3.89–11.95)	<0.001
PC <sub>20</sub> ≤8 mg/ml at any assessment from 9–15 yr	4.24 (2.64–6.79)	<0.001	6.93 (4.07–11.77)	<0.001
PC <sub>20</sub> ≤8 mg/ml or BDR at any assessment to 21 yr	4.13 (2.59–6.59)	<0.001	7.22 (4.29–12.17)	<0.001
Positive skin test for house-dust-mite allergen at 13 yr	3.38 (2.12–5.37)	<0.001	4.17 (2.49–7.01)	<0.001
Positive skin test for cat allergen at 13 yr	2.81 (1.65–4.79)	<0.001	3.27 (1.78–6.03)	<0.001
Smoking at 21 yr	2.05 (1.30–3.24)	0.002	1.84 (1.11–3.04)	0.02
Father smoked when study member was a child	0.63 (0.40–1.00)	0.05	1.29 (0.79–2.11)	0.31
Mother smoked when study member was a child	0.84 (0.53–1.37)	0.46	0.98 (0.60–1.61)	0.93
Family history of wheezing	1.44 (0.92–2.27)	0.11	1.59 (0.98–2.60)	0.06
Age at onset of wheezing†	0.97 (0.94–1.01)	0.11	0.87 (0.83–0.91)	<0.001
Female sex	1.37 (0.87–2.16)	0.17	0.95 (0.58–1.55)	0.84
Multivariate (significant factors only)				
PC <sub>20</sub> ≤8 mg/ml or BDR >10% at any assessment from 9–21 yr	3.00 (1.71–5.26)	<0.001	3.03 (1.65–5.55)	<0.001
Positive skin test for house-dust-mite allergen at 13 yr	2.41 (1.42–4.09)	0.001	2.18 (1.18–4.00)	0.01
Female sex	1.71 (1.04–2.82)	0.03	—	—
Smoking at 21 yr	1.84 (1.13–3.00)	0.01	—	—
Age at onset of wheezing†	—	—	0.89 (0.85–0.94)	<0.001


\* The odds ratio (OR) for persistence of wheezing is for the comparison with all other study members except those who never reported wheezing. The OR for relapse is for the comparison with all other study members except those with persistent wheezing and those who never reported wheezing. CI denotes confidence interval, PC<sub>20</sub> the concentration of methacholine causing a 20 percent decrease in the forced expiratory volume in one second (FEV<sub>1</sub>), and BDR the response of the FEV<sub>1</sub> to a bronchodilator (increase from base line).

† The OR was calculated for persistence or relapse per year of increase in the age at onset (i.e., a later age at onset was protective).

outcomes. There were significant differences in the prevalences of childhood asthma, wheezing, and atopy between the 613 study members for whom respiratory data were available at all assessments (59.1 percent) and those for whom respiratory data were not available at all assessments, but there were no differences in outcome characteristics at the final assessment, at the age of 26 years. Because our multidisciplinary study evaluated many aspects of health and development other than asthma and allergy, this approach reduced the likelihood that the decision to return for each assessment was biased by the presence of these conditions, thus increasing generalizability.

Wheezing was common in this cohort, reported at some time by 72.6 percent of the 613 study members. This high cumulative prevalence, which may be slightly biased upward for reasons noted above, includes the 21.2 percent of study members who reported wheezing at only one assessment. The lat-

ter group differed from those who never reported wheezing in having almost double the prevalence of atopy to house dust mites, and therefore this group could not be ignored. We have previously compared the responses of 946 study members assessed at the age of 21 years with those of 991 subjects 20 to 22 years old who were enrolled in the cross-sectional European Community Respiratory Health Survey, performed elsewhere in New Zealand. This comparison showed no significant or systematic differences in the prevalence of reported wheezing in the previous 12 months, waking with chest symptoms, attacks of asthma, and use of asthma medication,<sup>26</sup> thus providing evidence that our high prevalence rates are not biased by the longitudinal design. In a birth cohort from the United Kingdom, 43 percent of the cohort members reported wheezing by the age of 33 years,<sup>12</sup> a result suggesting, as does our study, that wheezing is very common but is often mild and transient.



As young adults, 26.9 percent of our cohort had continuing symptoms of asthma; 14.5 percent had persistent wheezing from onset with no remission, and 12.4 percent had relapsed after remission. These study members represent over one third of the 72.6 percent who reported ever wheezing, a result consistent with Australian studies in Tasmania<sup>10</sup> and Melbourne,<sup>13</sup> in which two thirds of subjects with asthma “outgrew” their disease.<sup>6</sup>

An early age at onset was a risk factor for relapse. The odds ratio of 0.89 indicates the protective effect per year of increase in the age at onset. According to this model, the risk for children with a 10-year-later age at onset was 0.89<sup>10</sup>, or 0.31 — that is, a 10-year-later age at onset reduced the risk of relapse by 69 percent.

Assessing outcomes relatively early in adult life may overestimate the number of remissions and underestimate the number of relapses, because symptoms may recur later. In a study in Tucson, Arizona, remission was most likely in adolescence and was uncommon in adulthood.<sup>27</sup> Another limitation of our study is that histories of wheezing in early childhood were obtained when the children were already nine years old. Our study therefore indicates the likelihood of persistence or relapse among children whose mothers recalled that they wheezed in early childhood or in whom wheezing developed subsequently. However, early-childhood wheezing not recalled by the mother had probably been mild and

had remitted, since otherwise one would expect these symptoms to be recalled.

Lung function was persistently impaired throughout childhood in study members with persistent asthma in adulthood, a phenomenon known as tracking. However, the slopes of change in FEV<sub>1</sub>:FVC were similar in each group, indicating that impairment of lung function occurred in early childhood, before our first measurements at the age of nine years. Children with atopy may have impaired lung function as early as three years of age.<sup>28</sup> Lung function in male study members with a relapse tracked closely with that in male study members with persistent asthma, whereas female study members with a relapse had lower lung function only as adults. This difference may be due to the greater severity of disease among young boys with asthma.

The impairment in lung function in the group with persistent asthma was greater in those with persistent airway hyperresponsiveness and in those treated with inhaled corticosteroids. This finding illustrates confounding by severity, since the use of inhaled corticosteroids is an indicator of more severe disease, not the cause of impaired lung function. In the Melbourne longitudinal study, adult lung function was impaired in subjects with current severe asthma, but not in those with milder asthma who were not using inhaled corticosteroids, whereas those who were asymptomatic for three years had normal lung function, even though they had had

asthma throughout childhood.<sup>13,16</sup> Our study extends the findings of the birth-cohort study from the United Kingdom<sup>15</sup> by showing that reduced lung function in adulthood among those with persistent asthma is evident early in childhood and has consistently been at this lower level throughout childhood and adolescence into adulthood.

In the United Kingdom birth cohort, smoking was a risk factor for the development of asthma between 17 and 33 years of age and was a strong predictor of relapse of earlier asthma by the age of 33 years.<sup>12</sup> In our study, smoking at 21 years of age was predictive of persistent wheezing in both univariate and multivariate analyses and of relapse of wheezing in univariate but not in multivariate analysis. In studies based on asthma-clinic populations, the effect of smoking on the persistence of asthma has been inconsistent, perhaps reflecting self-selection (the "healthy smoker" effect).<sup>7</sup>

In summary, in a population-based birth cohort

of New Zealand children who were not selected because they had asthma or were at high risk, the independent risk factors for persistent asthma in adulthood included allergy to house dust mites, smoking, airway hyperresponsiveness, and female sex. The independent risk factors for relapse after remission included allergy to house dust mites, airway hyperresponsiveness, and early age at onset. Those with persistent or relapsing asthma had substantially impaired lung function at each assessment during childhood, adolescence, and adulthood, a result suggesting that these outcomes are determined early in childhood. The challenge is to develop identification and treatment strategies applicable to early childhood that will reduce these adverse outcomes.

Supported by funds from the Health Research Council of New Zealand, the Otago Medical Research Foundation, the New Zealand Lottery Grants Board, and the Asthma Foundation of New Zealand.

We are indebted to Air New Zealand; to the study members and their families for their ongoing commitment and support; to Dr. Wendy Lou for statistical assistance; and to Mrs. Pearl Davis and Mrs. Jan Kettink for secretarial and administrative assistance.

#### REFERENCES

1. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinconjunctivitis, and atopic eczema: ISAAC. *Lancet* 1998;351:1225-32.
2. Downs SH, Marks GB, Sporik R, Belosouva EG, Car NG, Peat JK. Continued increase in the prevalence of asthma and atopy. *Arch Dis Child* 2001;84:20-3.
3. Ulrik CS, Backer V, Hesse B, Dirksen A. Risk factors for development of asthma in children and adolescents: findings from a longitudinal population study. *Respir Med* 1996;90:623-30.
4. Grol MH, Gerritsen J, Vonk JM, et al. Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years: a 30-year follow-up study. *Am J Respir Crit Care Med* 1999;160:1830-7.
5. Rhodes HL, Thomas P, Sporik R, Holgate ST, Cogswell JJ. A birth cohort study of subjects at risk of atopy: twenty-two-year follow-up of wheeze and atopic status. *Am J Respir Crit Care Med* 2002;165:176-80.
6. Sears MR. Growing up with asthma. *BMJ* 1994;309:72-3.
7. Grol MH, Gerritsen J, Postma DS. Asthma: from childhood to adulthood. *Allergy* 1996;51:855-69.
8. Ulrik CS. Outcome of asthma: longitudinal changes in lung function. *Eur Respir J* 1999;13:904-18.
9. Rhodes H, Sporik R, Thomas P, Holgate ST, Cogswell JJ. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. *J Allergy Clin Immunol* 2001;108:720-5.
10. Jenkins MA, Hopper JL, Bowes G, Carlin JB, Flander LB, Giles GG. Factors in childhood as predictors of asthma in adult life. *BMJ* 1994;309:90-3.
11. Xuan W, Marks GB, Toelle BG, et al. Risk factors for onset and remission of atopy, wheeze, and airway hyperresponsiveness. *Thorax* 2002;57:104-9.
12. Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. *BMJ* 1996;312:1195-9.
13. Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. *J Allergy Clin Immunol* 2002;109:189-94.
14. Xuan W, Peat JK, Toelle BG, Marks GB, Berry G, Woolcock AJ. Lung function growth and its relation to airway hyperresponsiveness and recent wheeze: results from a longitudinal population study. *Am J Respir Crit Care Med* 2000;161:1820-4.
15. Strachan DP, Griffiths JM, Johnston IDA, Anderson HR. Ventilatory function in British adults after asthma or wheezing illness at ages 0-35. *Am J Respir Crit Care Med* 1996;154:1629-35.
16. Oswald H, Phelan PD, Lanigan A, et al. Childhood asthma and lung function in mid-adult life. *Pediatr Pulmonol* 1997;23:14-20.
17. Silva PA, Stanton WR. From child to adult: the Dunedin multidisciplinary health and development study. Auckland, New Zealand: Oxford University Press, 1996.
18. Sears MR, Holdaway MD, Flannery EM, Herbison GP, Silva PA. Parental and neonatal risk factors for atopy, airway hyperresponsiveness, and asthma. *Arch Dis Child* 1996;75:392-8.
19. Jones DT, Sears MR, Holdaway MD, et al. Childhood asthma in New Zealand. *Br J Dis Chest* 1987;81:332-40.
20. Sears MR, Herbison GP, Holdaway MD, Hewitt CJ, Flannery EM, Silva PA. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. *Clin Exp Allergy* 1989;19:419-24.
21. Sears MR, Jones DT, Holdaway MD, et al. Prevalence of bronchial reactivity to inhaled methacholine in New Zealand children. *Thorax* 1986;41:283-9.
22. Burney P, Chinn S. Developing a new questionnaire for measuring the prevalence and distribution of asthma. *Chest* 1987;91: Suppl:79S-83S.
23. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). *Am Rev Respir Dis* 1978;118:1-120.
24. Sinclair SW, Avery SF, Brady DM, Smith DA, Holst PE, O'Donnell TV. Prediction formulae for normal pulmonary function values in New Zealand European subjects. *N Z Med J* 1980;91:1-5.
25. Chai H, Farr RS, Froehlich LA, et al. Standardization of bronchial inhalation challenge procedures. *J Allergy Clin Immunol* 1975;56:323-7.
26. Sears MR, Lewis S, Herbison GP, et al. Comparison of reported prevalences of recent asthma in longitudinal and cross-sectional studies. *Eur Respir J* 1997;10:51-4.
27. Bronnimann S, Burrows B. A prospective study of the natural history of asthma: remission and relapse rates. *Chest* 1986;90:480-4.
28. Lowe L, Murray CS, Custovic A, Simpson BM, Kissen PM, Woodcock A. Specific airway resistance in 3-year-old children: a prospective cohort study. *Lancet* 2002;359:1904-8.

Copyright © 2003 Massachusetts Medical Society.